XML 55 R45.htm IDEA: XBRL DOCUMENT v3.23.3
Loan Payable to Silicon Valley Bank (Details Narrative) - USD ($)
Apr. 02, 2020
Oct. 17, 2019
Sep. 30, 2023
Oct. 31, 2019
Dec. 31, 2017
Mar. 23, 2017
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Interest rate     5.50%      
Warrants to purchase, shares     819,767      
Warrant [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Warrants to purchase, shares         412 366
Warrant exercise price, per share         $ 97.00 $ 109.20
Amended Loan Agreement [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Interest rate   5.00%        
Amended Loan Agreement [Member] | Bank Warrant [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Debt instrument, final payment       $ 200,000    
Warrants to purchase, shares   4,928        
Warrant exercise price, per share   $ 33.80        
Amended Loan Agreement [Member] | Share-Based Payment Arrangement, Tranche One [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Line of credit, current   $ 3,000,000        
Repayments of lines of credit   400,000        
Debt instrument, final payment   116,000        
Amended Loan Agreement [Member] | Share-Based Payment Arrangement, Tranche Two [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Line of credit, current   2,000,000        
Additional paid in capital   $ 20,000,000        
Line of credit facility, maximum borrowing capacity     $ 2      
Amended Loan Agreement [Member] | Share-Based Payment Arrangement, Tranche Two [Member] | Bank Warrant [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Percentage for warrant exercise price per share   0.02%        
Diluted equity outstanding   $ 1,000,000        
Loan Deferral Agreement [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Debt instrument maturity date description Under the Loan Deferral Agreement, the Bank agreed to (i) extend the scheduled maturity date of the Amended Loan Agreement from March 31, 2022 to September 30, 2022, and (ii) deferred the principal payments by an additional 6 months whereby payments of interest only on the Bank loan principal balance will be due monthly from May 1, 2020 through October 1, 2020, followed by 23 monthly payments of principal and interest beginning on November 1, 2020, all provided at no additional fees to Oncocyte.